vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and RBC Bearings INC (RBC). Click either name above to swap in a different company.
RBC Bearings INC is the larger business by last-quarter revenue ($461.6M vs $284.0M, roughly 1.6× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 14.6%, a 81.7% gap on every dollar of revenue. On growth, RBC Bearings INC posted the faster year-over-year revenue change (17.0% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 5.6%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Dover Corporation is an American conglomerate manufacturer of industrial products. The Downers Grove, Illinois-based company was founded in 1955. As of 2021, Dover's business was divided into five segments: Engineered Products, Clean Energy and Fueling, Imaging & Identification, Pumps & Process Solutions and Climate and Sustainability Technologies. Dover is a constituent of the S&P 500 index and trades on the New York Stock Exchange under the symbol DOV. Dover was ranked 448 in the 2024 Fortu...
ACAD vs RBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $461.6M |
| Net Profit | $273.6M | $67.4M |
| Gross Margin | 90.8% | 44.3% |
| Operating Margin | 6.1% | 22.3% |
| Net Margin | 96.3% | 14.6% |
| Revenue YoY | 9.4% | 17.0% |
| Net Profit YoY | 90.3% | 16.4% |
| EPS (diluted) | $1.61 | $2.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $461.6M | ||
| Q3 25 | $278.6M | $455.3M | ||
| Q2 25 | $264.6M | $436.0M | ||
| Q1 25 | $244.3M | $437.7M | ||
| Q4 24 | $259.6M | $394.4M | ||
| Q3 24 | $250.4M | $397.9M | ||
| Q2 24 | $242.0M | $406.3M | ||
| Q1 24 | $205.8M | $413.7M |
| Q4 25 | $273.6M | $67.4M | ||
| Q3 25 | $71.8M | $60.0M | ||
| Q2 25 | $26.7M | $68.5M | ||
| Q1 25 | $19.0M | $72.7M | ||
| Q4 24 | $143.7M | $57.9M | ||
| Q3 24 | $32.8M | $54.2M | ||
| Q2 24 | $33.4M | $61.4M | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 90.8% | 44.3% | ||
| Q3 25 | 92.2% | 44.1% | ||
| Q2 25 | 92.2% | 44.8% | ||
| Q1 25 | 91.7% | 44.2% | ||
| Q4 24 | 91.6% | 44.3% | ||
| Q3 24 | 92.5% | 43.7% | ||
| Q2 24 | 92.5% | 45.3% | ||
| Q1 24 | 88.8% | 43.1% |
| Q4 25 | 6.1% | 22.3% | ||
| Q3 25 | 12.8% | 21.5% | ||
| Q2 25 | 12.2% | 23.2% | ||
| Q1 25 | 7.9% | 23.0% | ||
| Q4 24 | 59.1% | 21.7% | ||
| Q3 24 | 12.6% | 21.6% | ||
| Q2 24 | 12.6% | 24.0% | ||
| Q1 24 | 7.4% | 22.8% |
| Q4 25 | 96.3% | 14.6% | ||
| Q3 25 | 25.8% | 13.2% | ||
| Q2 25 | 10.1% | 15.7% | ||
| Q1 25 | 7.8% | 16.6% | ||
| Q4 24 | 55.4% | 14.7% | ||
| Q3 24 | 13.1% | 13.6% | ||
| Q2 24 | 13.8% | 15.1% | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | $2.13 | ||
| Q3 25 | $0.42 | $1.90 | ||
| Q2 25 | $0.16 | $2.17 | ||
| Q1 25 | $0.11 | $2.33 | ||
| Q4 24 | $0.86 | $1.82 | ||
| Q3 24 | $0.20 | $1.65 | ||
| Q2 24 | $0.20 | $1.90 | ||
| Q1 24 | $0.10 | $1.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $107.6M |
| Total DebtLower is stronger | — | $990.2M |
| Stockholders' EquityBook value | $1.2B | $3.3B |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $107.6M | ||
| Q3 25 | $258.0M | $91.2M | ||
| Q2 25 | $253.6M | $132.9M | ||
| Q1 25 | $217.7M | $36.8M | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | $76.8M | ||
| Q1 24 | $204.7M | $63.5M |
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $1.2B | $3.3B | ||
| Q3 25 | $917.3M | $3.2B | ||
| Q2 25 | $822.4M | $3.1B | ||
| Q1 25 | $765.2M | $3.0B | ||
| Q4 24 | $732.8M | $2.9B | ||
| Q3 24 | $577.2M | $2.9B | ||
| Q2 24 | $516.7M | $2.8B | ||
| Q1 24 | $464.0M | $2.8B |
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.3B | $5.1B | ||
| Q2 25 | $1.2B | $4.8B | ||
| Q1 25 | $1.1B | $4.7B | ||
| Q4 24 | $1.2B | $4.7B | ||
| Q3 24 | $976.9M | $4.7B | ||
| Q2 24 | $914.1M | $4.7B | ||
| Q1 24 | $855.1M | $4.7B |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $122.1M |
| Free Cash FlowOCF − Capex | — | $99.1M |
| FCF MarginFCF / Revenue | — | 21.5% |
| Capex IntensityCapex / Revenue | — | 5.0% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $122.1M | ||
| Q3 25 | $74.3M | $88.4M | ||
| Q2 25 | $64.0M | $120.0M | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | $84.0M | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | $25.0M | $97.4M | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | $99.1M | ||
| Q3 25 | $73.9M | $71.7M | ||
| Q2 25 | — | $104.3M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $73.6M | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | $88.4M | ||
| Q1 24 | — | — |
| Q4 25 | — | 21.5% | ||
| Q3 25 | 26.5% | 15.7% | ||
| Q2 25 | — | 23.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 18.7% | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | 21.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 5.0% | ||
| Q3 25 | 0.1% | 3.7% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 0.0% | 4.1% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | 1.81× | ||
| Q3 25 | 1.03× | 1.47× | ||
| Q2 25 | 2.40× | 1.75× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | 1.45× | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | 1.59× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
